



# Kabra Drugs Limited

CIN NO : L02423MP1989PLC005438

Corp. Off : No.3, 2nd Floor, Swaminathan Street, West Mambalam, Chennai - 600 033.

Date: 29<sup>th</sup> May 2026

To,  
BSE Limited  
Phiroze Jeejeebhoy Towers  
21<sup>st</sup> Floor, Dalal Street  
Mumbai – 400001

**BSE Scrip Code: 524322**

**Sub: Undertaking for Non- Applicability of Regulation 32 of SEBI (LODR) Regulations, 2015 for the quarter ended on 31<sup>st</sup> March 2026.**

Dear Sir/Madam,

As per Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the listed entity shall submit to the stock exchange the following statement(s) for quarter ended on 31<sup>st</sup> March 2026 for public issue, rights issue, preferential issue etc. –

(a) Indicating deviations, if any, in the use of proceeds from the objects stated in the offer document or explanatory statement to the notice for the general meeting, as applicable;

(b) Indicating category wise variation (capital expenditure, sales and marketing, working capital etc.) between projected utilization of funds made by it in its offer document or explanatory statement to the notice for the general meeting, as applicable and the actual utilization of funds.

In view of the aforesaid, I, the undersigned, Mr. Nanjappan Aravind, Managing Director of Kabra Drugs Limited hereby certify that Compliances of Regulation 32 of SEBI (LODR) Regulations, 2015 is not applicable to the company as the company has not issued any share by way of public issue, right issue, preferential issue etc. for the quarter ended on 31st March 2026.

Kindly take the aforesaid information on record and oblige.

Thanking you,

Yours sincerely,

**For Kabra Drugs Limited**

**Nanjappan Aravind**  
**Managing Director**  
**DIN: 01895602**

